GlassScriptPhysician profile
Adeel Choudhary
NPI 1497140081
$1,364.07
in general payments reported to CMS, 2019-2025
18 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $302 · 2023: $271 · 2024: $191 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $855.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $233.74 | 2021-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $223.98 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.63 | 2021-2025 | Lifevest |
| Alexion Pharmaceuticals, INC. | $141.88 | 2023-2024 | Soliris |
| Pfizer INC. | $126.68 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.45 | 2022-2024 | Jardiance, Stiolto Respimat, Combivent Respimat |
| Smith+Nephew, INC. | $74.48 | 2025 | Collagenase Santyl |
| Astrazeneca Pharmaceuticals LP | $65.24 | 2022-2023 | Lokelma |
| Abbott Laboratories | $44.28 | 2023-2025 | Freestyle Libre, Freestyle Libre 3 |
| Boston Scientific Corporation | $38.43 | 2025 | General - Therapies |
| Genzyme Corporation | $25.68 | 2024 | |
| Stryker Corporation | $25.03 | 2022 | |
| Solventum Corporation | $20.65 | 2024 | V.A.C. Veraflo Cleanse Choice |
| Amgen INC. | $20.34 | 2025 | Repatha |
| La Jolla Pharmaceutical Company | $20.15 | 2024 | Xerava |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2023 | Xifaxan |
| Mylan Specialty L.P. | $19.06 | 2024 | Yupelri |
| Melinta Therapeutics, LLC | $16.37 | 2025 | Orbactiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeel Choudhary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.